Form 8-K - Current report:
SEC Accession No. 0001193125-25-087955
Filing Date
2025-04-22
Accepted
2025-04-22 08:58:51
Documents
18
Period of Report
2025-04-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d934084d8k.htm   iXBRL 8-K 40270
2 EX-4.1 d934084dex41.htm EX-4.1 74976
3 EX-10.1 d934084dex101.htm EX-10.1 24873
4 EX-10.2 d934084dex102.htm EX-10.2 34849
5 EX-10.3 d934084dex103.htm EX-10.3 28687
6 EX-10.4 d934084dex104.htm EX-10.4 76026
  Complete submission text file 0001193125-25-087955.txt   472855

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA rntx-20250421.xsd EX-101.SCH 2515
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE rntx-20250421_lab.xml EX-101.LAB 17957
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rntx-20250421_pre.xml EX-101.PRE 11241
21 EXTRACTED XBRL INSTANCE DOCUMENT d934084d8k_htm.xml XML 3760
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Rein Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38130 | Film No.: 25855661
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)